Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.
Identifieur interne : 000145 ( PubMed/Corpus ); précédent : 000144; suivant : 000146Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.
Auteurs : Tiago A. Mestre ; Erik Van Duijn ; Aileen M. Davis ; Anne-Catherine Bachoud-Lévi ; Monica Busse ; Karen E. Anderson ; Joaquim J. Ferreira ; Philipp Mahlknecht ; Vitor Tumas ; Cristina Sampaio ; Chris G. Goetz ; Esther Cubo ; Glenn T. Stebbins ; Pablo Martinez-MartinSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2016.
Abstract
Behavioral symptoms are an important feature of Huntington's disease and contribute to impairment in quality of life. The Movement Disorder Society commissioned the assessment of the clinimetric properties of rating scales in Huntington's disease to make recommendations regarding their use, following previously used standardized criteria. A systematic literature search was conducted to identify the scales used to assess behavioral symptoms in Huntington's disease. For the purpose of this review, 7 behavioral domains were deemed significant in Huntington's disease: irritability, anxiety, depression, apathy, obsessive-compulsive behaviors, psychosis, and suicidal ideation. We included a total of 27 behavioral rating scales, 19 of which were of a single behavioral domain and the remaining 8 scales included multiple behavioral domains. Three rating scales were classified as "recommended" exclusively for screening purposes: the Irritability Scale for irritability, the Beck Depression Inventory-II, and the Hospital Anxiety and Depression Scale for depression. There were no "recommended" scales for other purposes such as diagnosis, severity, or change in time or to treatment. The main challenges identified for assessment of behavioral symptoms in Huntington's disease are the co-occurrence of multiple behavioral symptoms, the particular features of a behavioral symptom in Huntington's disease, and the need to address stage- and disease-specific features, including cognitive impairment and lack of insight. The committee concluded that there is a need to further validate currently available behavioral rating scales in Huntington's disease to address gaps in scale validation for specific behavioral domains and purpose of use. © 2016 International Parkinson and Movement Disorder Society.
DOI: 10.1002/mds.26675
PubMed: 27296904
Links to Exploration step
pubmed:27296904Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.</title><author><name sortKey="Mestre, Tiago A" sort="Mestre, Tiago A" uniqKey="Mestre T" first="Tiago A" last="Mestre">Tiago A. Mestre</name><affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada. tmestre@toh.on.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Van Duijn, Erik" sort="Van Duijn, Erik" uniqKey="Van Duijn E" first="Erik" last="Van Duijn">Erik Van Duijn</name><affiliation><nlm:affiliation>Psychiatry Department, Leiden University Medical Centre, and Centre for Mental Health Care Delfland, Delft, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Davis, Aileen M" sort="Davis, Aileen M" uniqKey="Davis A" first="Aileen M" last="Davis">Aileen M. Davis</name><affiliation><nlm:affiliation>Krembil Research Institute, University Health Network and Institute of Health Policy, Management and Evaluation and Rehabilitation Institute, University of Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Bachoud Levi, Anne Catherine" sort="Bachoud Levi, Anne Catherine" uniqKey="Bachoud Levi A" first="Anne-Catherine" last="Bachoud-Lévi">Anne-Catherine Bachoud-Lévi</name><affiliation><nlm:affiliation>Assistance Publique-Hôpitaux De Paris, National Centre of Reference for Huntington's Disease, Neurology Department, Université Paris Est, Créteil; INSERM U955 E01, Institut Mondor De Recherché Biomédicale, École Normale Supérieure, Créteil-Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Busse, Monica" sort="Busse, Monica" uniqKey="Busse M" first="Monica" last="Busse">Monica Busse</name><affiliation><nlm:affiliation>School of Healthcare Sciences, Cardiff University, Cardiff, Wales, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Anderson, Karen E" sort="Anderson, Karen E" uniqKey="Anderson K" first="Karen E" last="Anderson">Karen E. Anderson</name><affiliation><nlm:affiliation>Georgetown University, School of Medicine, Washington, District of Columbia, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name><affiliation><nlm:affiliation>Neurology and Clinical Pharmacology, University of Lisbon, Institute of Molecular Medicine, Lisbon, Portugal.</nlm:affiliation></affiliation></author><author><name sortKey="Mahlknecht, Philipp" sort="Mahlknecht, Philipp" uniqKey="Mahlknecht P" first="Philipp" last="Mahlknecht">Philipp Mahlknecht</name><affiliation><nlm:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Tumas, Vitor" sort="Tumas, Vitor" uniqKey="Tumas V" first="Vitor" last="Tumas">Vitor Tumas</name><affiliation><nlm:affiliation>Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><nlm:affiliation>CHDI Management/CHDI Foundation, Princeton, New Jersey, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Goetz, Chris G" sort="Goetz, Chris G" uniqKey="Goetz C" first="Chris G" last="Goetz">Chris G. Goetz</name><affiliation><nlm:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cubo, Esther" sort="Cubo, Esther" uniqKey="Cubo E" first="Esther" last="Cubo">Esther Cubo</name><affiliation><nlm:affiliation>Department of Neurology, Hospital Universitário Hermanos Yagüe, Burgos, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T" last="Stebbins">Glenn T. Stebbins</name><affiliation><nlm:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><nlm:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27296904</idno><idno type="pmid">27296904</idno><idno type="doi">10.1002/mds.26675</idno><idno type="wicri:Area/PubMed/Corpus">000145</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000145</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.</title><author><name sortKey="Mestre, Tiago A" sort="Mestre, Tiago A" uniqKey="Mestre T" first="Tiago A" last="Mestre">Tiago A. Mestre</name><affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada. tmestre@toh.on.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Van Duijn, Erik" sort="Van Duijn, Erik" uniqKey="Van Duijn E" first="Erik" last="Van Duijn">Erik Van Duijn</name><affiliation><nlm:affiliation>Psychiatry Department, Leiden University Medical Centre, and Centre for Mental Health Care Delfland, Delft, Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Davis, Aileen M" sort="Davis, Aileen M" uniqKey="Davis A" first="Aileen M" last="Davis">Aileen M. Davis</name><affiliation><nlm:affiliation>Krembil Research Institute, University Health Network and Institute of Health Policy, Management and Evaluation and Rehabilitation Institute, University of Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Bachoud Levi, Anne Catherine" sort="Bachoud Levi, Anne Catherine" uniqKey="Bachoud Levi A" first="Anne-Catherine" last="Bachoud-Lévi">Anne-Catherine Bachoud-Lévi</name><affiliation><nlm:affiliation>Assistance Publique-Hôpitaux De Paris, National Centre of Reference for Huntington's Disease, Neurology Department, Université Paris Est, Créteil; INSERM U955 E01, Institut Mondor De Recherché Biomédicale, École Normale Supérieure, Créteil-Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Busse, Monica" sort="Busse, Monica" uniqKey="Busse M" first="Monica" last="Busse">Monica Busse</name><affiliation><nlm:affiliation>School of Healthcare Sciences, Cardiff University, Cardiff, Wales, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Anderson, Karen E" sort="Anderson, Karen E" uniqKey="Anderson K" first="Karen E" last="Anderson">Karen E. Anderson</name><affiliation><nlm:affiliation>Georgetown University, School of Medicine, Washington, District of Columbia, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name><affiliation><nlm:affiliation>Neurology and Clinical Pharmacology, University of Lisbon, Institute of Molecular Medicine, Lisbon, Portugal.</nlm:affiliation></affiliation></author><author><name sortKey="Mahlknecht, Philipp" sort="Mahlknecht, Philipp" uniqKey="Mahlknecht P" first="Philipp" last="Mahlknecht">Philipp Mahlknecht</name><affiliation><nlm:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Tumas, Vitor" sort="Tumas, Vitor" uniqKey="Tumas V" first="Vitor" last="Tumas">Vitor Tumas</name><affiliation><nlm:affiliation>Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><nlm:affiliation>CHDI Management/CHDI Foundation, Princeton, New Jersey, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Goetz, Chris G" sort="Goetz, Chris G" uniqKey="Goetz C" first="Chris G" last="Goetz">Chris G. Goetz</name><affiliation><nlm:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cubo, Esther" sort="Cubo, Esther" uniqKey="Cubo E" first="Esther" last="Cubo">Esther Cubo</name><affiliation><nlm:affiliation>Department of Neurology, Hospital Universitário Hermanos Yagüe, Burgos, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T" last="Stebbins">Glenn T. Stebbins</name><affiliation><nlm:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><nlm:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Behavioral symptoms are an important feature of Huntington's disease and contribute to impairment in quality of life. The Movement Disorder Society commissioned the assessment of the clinimetric properties of rating scales in Huntington's disease to make recommendations regarding their use, following previously used standardized criteria. A systematic literature search was conducted to identify the scales used to assess behavioral symptoms in Huntington's disease. For the purpose of this review, 7 behavioral domains were deemed significant in Huntington's disease: irritability, anxiety, depression, apathy, obsessive-compulsive behaviors, psychosis, and suicidal ideation. We included a total of 27 behavioral rating scales, 19 of which were of a single behavioral domain and the remaining 8 scales included multiple behavioral domains. Three rating scales were classified as "recommended" exclusively for screening purposes: the Irritability Scale for irritability, the Beck Depression Inventory-II, and the Hospital Anxiety and Depression Scale for depression. There were no "recommended" scales for other purposes such as diagnosis, severity, or change in time or to treatment. The main challenges identified for assessment of behavioral symptoms in Huntington's disease are the co-occurrence of multiple behavioral symptoms, the particular features of a behavioral symptom in Huntington's disease, and the need to address stage- and disease-specific features, including cognitive impairment and lack of insight. The committee concluded that there is a need to further validate currently available behavioral rating scales in Huntington's disease to address gaps in scale validation for specific behavioral domains and purpose of use. © 2016 International Parkinson and Movement Disorder Society.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27296904</PMID><DateCreated><Year>2016</Year><Month>06</Month><Day>14</Day></DateCreated><DateRevised><Year>2016</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>10</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.</ArticleTitle><Pagination><MedlinePgn>1466-1478</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26675</ELocationID><Abstract><AbstractText>Behavioral symptoms are an important feature of Huntington's disease and contribute to impairment in quality of life. The Movement Disorder Society commissioned the assessment of the clinimetric properties of rating scales in Huntington's disease to make recommendations regarding their use, following previously used standardized criteria. A systematic literature search was conducted to identify the scales used to assess behavioral symptoms in Huntington's disease. For the purpose of this review, 7 behavioral domains were deemed significant in Huntington's disease: irritability, anxiety, depression, apathy, obsessive-compulsive behaviors, psychosis, and suicidal ideation. We included a total of 27 behavioral rating scales, 19 of which were of a single behavioral domain and the remaining 8 scales included multiple behavioral domains. Three rating scales were classified as "recommended" exclusively for screening purposes: the Irritability Scale for irritability, the Beck Depression Inventory-II, and the Hospital Anxiety and Depression Scale for depression. There were no "recommended" scales for other purposes such as diagnosis, severity, or change in time or to treatment. The main challenges identified for assessment of behavioral symptoms in Huntington's disease are the co-occurrence of multiple behavioral symptoms, the particular features of a behavioral symptom in Huntington's disease, and the need to address stage- and disease-specific features, including cognitive impairment and lack of insight. The committee concluded that there is a need to further validate currently available behavioral rating scales in Huntington's disease to address gaps in scale validation for specific behavioral domains and purpose of use. © 2016 International Parkinson and Movement Disorder Society.</AbstractText><CopyrightInformation>© 2016 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mestre</LastName><ForeName>Tiago A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada. tmestre@toh.on.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Psychiatry Department, Leiden University Medical Centre, and Centre for Mental Health Care Delfland, Delft, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Aileen M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Krembil Research Institute, University Health Network and Institute of Health Policy, Management and Evaluation and Rehabilitation Institute, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachoud-Lévi</LastName><ForeName>Anne-Catherine</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Assistance Publique-Hôpitaux De Paris, National Centre of Reference for Huntington's Disease, Neurology Department, Université Paris Est, Créteil; INSERM U955 E01, Institut Mondor De Recherché Biomédicale, École Normale Supérieure, Créteil-Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busse</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Healthcare Sciences, Cardiff University, Cardiff, Wales, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Georgetown University, School of Medicine, Washington, District of Columbia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Joaquim J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Neurology and Clinical Pharmacology, University of Lisbon, Institute of Molecular Medicine, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahlknecht</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tumas</LastName><ForeName>Vitor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampaio</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CHDI Management/CHDI Foundation, Princeton, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Chris G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cubo</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital Universitário Hermanos Yagüe, Burgos, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stebbins</LastName><ForeName>Glenn T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Martin</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Members of the MDS Committee on Rating Scales Development</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Huntington's disease</Keyword><Keyword MajorTopicYN="N">anxiety</Keyword><Keyword MajorTopicYN="N">behavior</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">irritability</Keyword><Keyword MajorTopicYN="N">rating scales</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>04</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27296904</ArticleId><ArticleId IdType="doi">10.1002/mds.26675</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000145 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000145 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27296904
|texte= Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27296904" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |